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L E T T E R T O TH E E D I T O R
Response to ‘comment on “associations of statin use with
glycemic traits and incident type 2 diabetes”’
We welcome the comments on our article “Associations of statin use
with glycemic traits and incident type 2 diabetes1” by Sansome DJ
et al, which express the importance of bile acid (BA) as an important
metabolic regulator in the association of statins and glycaemic control
in type 2 diabetes (T2D).
As such, the authors highlighted the potential interactions of sta-
tins particularly at high doses in combination with glucose-lowering
therapy, namely, metformin, which leads to impaired glycaemic
control in patients with T2D. The effect of statins on regulating BA
homoeostasis in patients with T2D has been shown by several stud-
ies.2 It has been known that BA sequestrants may also reduce serum
glucose in patients with T2D.3 A recent meta-analysis of randomized
controlled trials (RCT) suggests that BA intake substantially improves
HbA1c and fasting glucose levels.4
In our study, we investigated the association of statin use in
two ways, first cross-sectionally with glycaemic traits and second
longitudinally with incident T2D, both among the general popula-
tion, therefore free of diabetes at the time of statin use. As we
described in the methods section of our manuscript, during follow-
up, we classified each participant into current use, past use and
never use of statins based on incident dates of T2D. From the date
of baseline centre visit and during follow-up, prevalent and incident
T2D cases were defined as a fasting serum glucose concentration
of ≥7.0 mmol/L or the use of glucose-lowering medications. We
excluded all prevalent T2D cases at baseline (n = 1165), and only
individuals with available data on statin use and baseline glycaemic
values (n = 9535) were included. Moreover, in a sensitivity analysis,
we examined the association between statins and risk of incident
T2D only in a subset of individuals (n = 6787) with normal baseline
fasting glucose concentrations (<6.1 mmol/L) by excluding cases of
impaired fasting glucose or prediabetes (n = 2748). Most impor-
tantly, to decrease the effect of reverse causality on our findings,
we further investigated the association of cumulative statin use
with incident T2D until one year before the onset of diabetes,
where the results still showed significant associations. Therefore,
the design of our study did not allow any possibility of including
patients with diabetes before starting statins. This design per se
does not allow using glucose-lowering medications either. Hence,
there was no concurrent use of statins and metformin in our study
population.
Theoretically, there are some potential underlying mechanisms
for the effect of statins in a population free of diabetes as we
highlighted the most important ones in our manuscript. We endorse
other potential underlying mechanisms as we have recently provided
evidence of DNA methylation as a possible mediator in the associa-
tion of statin use and T2D.5 Statins are widely prescribed to prevent
cardiovascular diseases. However, yet there is no reliable biomarker
to predict the diabetogenic effect on vulnerable patients. Complemen-
tary to genome-based studies, serum biomarkers discovery is an
emerging technology platform that offers the next level of information
needed to extend our pathophysiological insight into medication
response to treatment. Since genes, RNAs and proteins converge onto
the terminal downstream metabolome, metabolomics offers a rich
source of information in a complex and convoluted presentation. The
causal paths between different types, duration and dosages of statins,
metabolites and incident T2D remain unclear, though the effect of
statins on metabolites could also be explained by the altered gut
microbiome. A shred of recent evidence suggests that the modulation
of the gut microbiome by statins could partly explain the response to
this medication.6
In conclusion, we believe that further efforts should disentangle
the molecular effects of statin therapy on multiple metabolic
pathways. Metabolomics together with multi-omics data, for example,
gut microbiome, might provide new insights into statins mechanism of
action and development of diabetogenic effects in the general
population.
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